AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

JOHNSON & JOHNSON Director's Dealing 2024

Apr 10, 2024

29750_dirs_2024-04-10_27e8472d-004c-41af-b7e7-517d509f84fb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Contineum Therapeutics, Inc. (CTNM)
CIK: 0001855175
Period of Report: 2024-04-09

Reporting Person: JOHNSON & JOHNSON (10% Owner)
Reporting Person: Johnson & Johnson Innovation - JJDC, Inc. (10% Owner)

Holdings (Non-Derivative)

Security	Shares	Ownership
Class A Common Stock	1979173	Indirect

Footnotes

F1: The securities reported as indirectly beneficially owned by Johnson & Johnson are directly beneficially owned by Johnson & Johnson Innovation - JJDC, Inc., a wholly-owned subsidiary of Johnson & Johnson.